Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 1998 February;39(1) > The Journal of Cardiovascular Surgery 1998 February;39(1):99-102

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

ORIGINAL ARTICLES  CARDIAC PAPERS 

The Journal of Cardiovascular Surgery 1998 February;39(1):99-102

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

The Sorin Bicarbon valve: clinical evaluation in Israel

Borman J. B., Deviri E., Bitran D.*, Silberman Sh.*, Locker Ch.***, Yakirevich V.***, Sharoni R.**, Uretzky G.**

From Bikur Cholim Hospital, Jerusalem * Sha’arei Tzedek Medical Center, Jerusalem ** Carmel Medical Center, Haifa *** Ichilov Medical Center, Tel Aviv, Israel


PDF


Background. Four col­lab­o­rat­ing cen­ters ­pooled their ­results with the Sorin Bicarbon Bileaflet valve.
Material and methods. Between 6/91 and 11/95, 431 ­patients, 235 males and 196 ­females, under­went valve replace­ment using the new Sorin pros­the­sis; age range: 16-88, mean 61.4 yrs. Operations: AVR - 206, MVR - 177, TVR - 1, DVR - 47. Additional pro­ce­dures - 139: CAB - 117, valve ­repair - 22. AV sizes: 19-27, MV sizes: 21-33.
Results. Thirty day mor­tal­ity was 4.3%. Early com­pli­ca­tions includ­ed: CVA - 1.4%, +ve blood cul­ture - 2%, reop for bleed­ing - 5%. Late com­pli­ca­tions: infec­tive endo­car­ditis - 2.3%, valve throm­bo­sis - 0.2%, throm­boem­bo­li - 2.5%, major bleed­ing - 1.6%, reop­er­a­tion - 3%, late ­deaths (all caus­es) - 4.3%. No struc­tu­ral dete­ri­ora­tion has been report­ed with this valve and accept­able gra­dients have been ­observed. Hemolysis is neg­li­gible.
Conclusions. Based on this inter­me­di­ate expe­ri­ence the Sorin Bicarbon pros­the­sis is well-­designed with good hemo­dy­nam­ic prop­er­ties, and an accept­ably low inci­dence of com­pli­ca­tions.

inizio pagina